ArticleCommunications medicine2026

Canakinumab or emavusertib for anemia in lower-risk MDS: results of the CANFIRE and LUCAS phase 2, open-label, multicenter trials.

Anne Sophie Platzbecker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.